module.exports = [
    {
        articleID: "903975",
        componentNumber: 1, 
        slidePath: "903/975/903975_2",
        rawSlides: `<p><strong>&lt;&lt;insert slide 1; Chapter title: Program Introduction; 00:00&gt;&gt;</strong></p>

        <p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>The Big Debate: Pharmacologic vs Alternative Approaches in Smoking Cessation</strong></p>
        
        <p><strong>&lt;&lt;insert slide 2; 00:10&gt;&gt;</strong> </p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Program Agenda</strong></p>
        
        <p>&lt;&lt;Intra-activity question 1; 00:46&gt;&gt;  </p>
        
        <p>&lt;&lt;Intra-activity question 2; 00:51&gt;&gt;  </p>
        
        <p>&lt;&lt;Intra-activity question 3; 00:52&gt;&gt;  </p>
        
        <p><strong>&lt;&lt;level 1&gt;&gt; The Importance of a Complete Quit </strong></p>
        
        <p><strong>&lt;&lt;insert slide 3; Chapter title: The Importance of a Complete Quit; 00:53&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; The Importance of a Complete Quit</strong></p>
        
        <p><strong>&lt;&lt;insert slide 4; Chapter title: Morbidity and Mortality Related to Smoking; 01:00&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Worldwide Leading Causes of Attributable Global Mortality<sup>[1]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 5; 01:19&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Smoking Leads to an 11-Year Loss of Life Span<sup>[2]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 6; 01:37&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Mortality and Morbidity Rates Associated With Smoking<sup>[2,3]</sup></strong></p>
        
        <p>&#8226;	The figure on the left shows that there is a monotonous dose effect relationship between cigarettes per day and all-cause mortality</p>
        
        <p><tt>o	</tt>This means that even low smoking rates are associated with an increased risk of mortality </p>
        
        <p>&#8226;	In the specific case of cardiovascular disease, most of the mortality risk is borne by low smoking rates, as seen in the curve on the right </p>
        
        <p><strong>&lt;&lt;insert slide 7; 02:17&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Mortality and Morbidity Rates Associated With Smoking (cont)<sup>[2,4]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 8; Chapter title: Mortality Risk Reduction After Smoking Cessation or Reduction; 02:46&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; All-Cause Mortality Risk Reduction After Quitting Smoking<sup>[5]</sup></strong></p>
        
        <p>&#8226;	It is believed that complete quit is the safest and most effective way to reduce the all-cause mortality associated with smoking</p>
        
        <p>&#8226;	It is also believed that the reduction of all-cause mortality stabilizes roughly 10 to 15 years after complete smoking cessation</p>
        
        <p><strong>&lt;&lt;insert slide 9; 03:15&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Little Evidence of All-Cause Mortality Risk Reduction After Smoking Reduction<sup>[6-9]</sup></strong></p>
        
        <p>&#8226;	It is important to keep in mind that in all the studies shown on this slide, smoking reduction was not supported by any nicotine replacement use </p>
        
        <p>&#8226;	Moreover, it is known that reduction of cigarettes per day does not reflect reduction of toxin exposure</p>
        
        <p><strong>&lt;&lt;insert slide 1; 04:21&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Harm Reduction Concept: People Who Do Not Want to Give Up Tobacco or Nicotine Use Completely<sup>[10]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 11; 05:18&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt;Cigarette Smoking Causes the Most Harm<sup>[11]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 12; Chapter title: Conclusions; 06:42&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Conclusions</strong></p>
        
        <p><strong>&lt;&lt;level 1&gt;&gt; Pharmacologic Therapies for Smoking Cessation: The Evidence</strong></p>
        
        <p><strong>&lt;&lt;insert slide 13; Chapter title: Pharmacologic Therapies; 07:20&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Pharmacologic Therapies for Smoking Cessation: The Evidence</strong></p>
        
        <p><strong>&lt;&lt;insert slide 14; Chapter title: First-Line Drugs; 07:50&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Nicotine Replacement Therapy vs Control for Smoking Cessation<sup>[12]</sup></strong></p>
        
        <p>&#8226;	Nicotine replacement therapy is the oldest, most established, and most used therapy for smoking cessation</p>
        
        <p>&#8226;	Based on the results of this analysis, the Cochrane Group collaborators stated that they will never do another meta-analysis of this type, because the evidence is so strong for nicotine replacement against placebo</p>
        
        <p><tt>o	</tt>Subgroup and other types of analyses may be conducted, for example, comparing nicotine replacement with e-cigarettes or other comparators, but the placebo comparison is firmly established at this time</p>
        
        <p><strong>&lt;&lt;insert slide 15; 09:57&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; First-Line Drugs in Smoking Cessation: Meta-Analysis of Cochrane Register Efficacy Data<sup>[12-15]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 16; Chapter title: Varenicline; 11:44&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-12)<sup>[16-25]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 17; 12:48&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-52)<sup>[16,17,21-23,25]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 18; 13:11&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Quit Rates Flexible Quit Date Study<sup>[24]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 19; Chapter title: Maintenance Therapy With Varenicline; 13:34&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Varenicline Maintenance Study<sup>[26]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 20; 14:23&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Maintenance Treatment With Varenicline in Patients With Schizophrenia and Bipolar Disorder<sup>[27]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 21; Chapter title: EAGLES Study; 14:48&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; EAGLES: Continuous Abstinence Rates in Psychiatric and Nonpsychiatric Cohorts<sup>[28]</sup></strong></p>
        
        <p>&#8226;	This is the EAGLES study and included over 8000 subjects, both people with psychiatric disease and people without known psychiatric disease</p>
        
        <p>&#8226;	The study was sponsored by both producers of varenicline and of bupropion and in collaboration with health authorities</p>
        
        <p><strong>&lt;&lt;insert slide 22; 15:52&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Primary Endpoint for the EAGLES Study: Nonpsychiatric Adverse Events<sup>[28]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 23; Chapter title: Tolerability and Safety of Available Therapies; 16:57&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Tolerability and Safety Issues<sup>[29]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 24; Chapter title: Physician vs Patient Perspectives; 17:12&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Physician Perspectives<sup>[30]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 25; 19:20&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt;Lack of Readiness to Use Pharmacologic Options (Smoker)</strong></p>
        
        <p><strong>&lt;&lt;level 1&lt;&lt;insert slide 26 Chapter title: E-Cigarettes and "Heat-Not-Burn" Devices; 20:19&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; E-Cigarettes and "Heat-Not-Burn" Devices: Is There a Role?</strong></p>
        
        <p><strong>&lt;&lt;insert slide 27; Chapter title: The Current Controversy; 20:30&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Current Controversy</strong></p>
        
        <p>&#8226;	In my opinion, what we see in our field is this split in the attitude to e-cigarettes, which I believe is based on priority</p>
        
        <p>&#8226;	If the priority is smoke-related death and disease, then there is a sort of pragmatic perspective in which alternative lower-risk nicotine devices may appear as promising to lower the total of death and disease from smoking</p>
        
        <p>&#8226;	By contrast, the other view is the concern that providing nicotine in the less dangerous form still maintains and may even increase nicotine use in the population</p>
        
        <p><tt>o	</tt>Hence, safe nicotine devices are both a problem and a risk</p>
        
        <p><strong>&lt;&lt;insert slide 28; Chapter title: The UK Perspective on E-Cigarettes; 22:07&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Recent UK Reports Regarding the Use of E-Cigarettes<sup>[31-33]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 29; 22:19&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Conclusions of UK Reviews</strong></p>
        
        <p><strong>&lt;&lt;insert slide 30; 23:20&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; The Opposite View</strong></p>
        
        <p><strong>&lt;&lt;insert slide 31; 23:36&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Time Will Tell</strong></p>
        
        <p><strong>&lt;&lt;insert slide 32; 24:04&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; UK Experience So Far</strong></p>
        
        <p><strong>&lt;&lt;insert slide 33; 25:00&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; "Heat-Not-Burn" Products<sup>[34]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 34; 25:45&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Cigarette Sales Decline: Japan, 2014-2018</strong></p>
        
        <p><strong>&lt;&lt;insert slide 35; Chapter title: The DUO Study; 26:00&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt;The DUO Study<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 36; 26:11&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Background<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 37; 26:36&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; DUO Study<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 38; 26:50&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Study Procedures<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 39; 27:32&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Are Dual Users Interested in Varenicline?<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 40; 27:51&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Did Those Wanting and Not Wanting Varenicline Differ?<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 41; 28:31&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Quitting Outcomes<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 42; 28:44&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Quitting Vaping, Smoking, and Both<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 43; 29:07&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Changes in Enjoyment of Smoking and Vaping<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 44; 29:31&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Conclusions<sup>[35]</sup></strong></p>
        
        <p><strong>&lt;&lt;level 1&gt;&gt; Current Guidelines</strong></p>
        
        <p><strong>&lt;&lt;insert slide 45; Chapter title: Current Guidelines; 30:00&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; What Do the Guidelines Say?</strong></p>
        
        <p><strong>&lt;&lt;insert slide 46; Chapter title: WHO Recommendations; 30:10&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; WHO Framework Convention on Tobacco Control<sup>[36]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 47; 30:55&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; WHO Urges Restrictions on E-Cigarettes (2016)<sup>[37]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 48; 31:10&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Interventions to Reduce Harm From Continued Tobacco Use<sup>[10]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 49; Chapter title: NICE Guideline; 32:57&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; NICE 2018: 1.5 Advice on E-Cigarettes for Health and Social Care Workers in Primary and Community Settings<sup>[38]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 50; Chapter title: Analysis of National Guidelines; 33:26&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice<sup>[39]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 51; 34:04&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice (cont)<sup>[39]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 52; 35:42&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice (cont)<sup>[39]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 53; Chapter title: Canadian Guidelines; 36:25&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement<sup>[40]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 54; 36:32&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement (cont)<sup>[40]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 55; 36:40&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement (cont)<sup>[40]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 56; Chapter title: Medical Societies; 37:03&gt;&gt;</strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Medical Societies</strong></p>
        
        <p><strong>&lt;&lt;insert slide 57; 37:55&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; AHA Smoking Guidelines 2014</strong></p>
        
        <p><strong>&lt;&lt;insert slide 58; 38:46&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Position Statement of the Forum of International Respiratory Societies: E-Cigarettes<sup>[41]</sup></strong></p>
        
        <p><strong>&lt;&lt;insert slide 59; 39:42&gt;&gt; </strong> <strong>&lt;&lt;level 2&gt;&gt; Conclusions</strong></p>
        
        <p>&lt;&lt;Intra-activity question 1; 42:00&gt;&gt;  </p>
        
        <p>&lt;&lt;Intra-activity question 2; 42:02&gt;&gt;  </p>
        
        <p>&lt;&lt;Intra-activity question 3; 42:05&gt;&gt;  </p>
        
        <p><strong>&lt;&lt;insert slide 60; 42:08&gt;&gt; </strong></p>
        
        <p><strong>&lt;&lt;level 2&gt;&gt; Thank You</strong></p>
        
        <p><em>This content has been condensed for improved clarity.</em></p>`
    }
];